NEW YORK (GenomeWeb) – Atossa Genetics announced today that its subsidiary, the National Reference Laboratory for Breast Health, and BioVentive have reached a deal to market and promote NRLBH's services.
NRLBH is a CLIA-registered laboratory based in Seattle that offers anatomic and clinical pathology services and molecular-based testing. BioVentive provides sales and marketing services to healthcare companies.
In a statement, Atossa President and CEO Steven Quay said that BioVentive's sales force is "highly regarded by the medical community," and that he anticipates the company will play "a vital role as the NRLBH develops and commercializes its testing services."
Atossa develops tests and other medical devices, as well as laboratory services and therapeutics aimed at breast cancer. Its lab services are being developed by NRLBH. BioVentive has a sales force of 85 who will offer NRLBH's services throughout the US, Quay added.
Financial and other terms of the deal were not disclosed.
Last week Atossa announced it submitted additional information to the US Food and Drug Administration related to its 510(k) submission for the ForeCYTE Breast Aspirator.